Dong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dong Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bo Yang
Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
7 shared publicationsJiazheng Yuan
Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
7 shared publicationsShangqing Ren
Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China
7 shared publicationsYaoqian Wang
Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
7 shared publicationsYi Wei
Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
7 shared publicationsCheng Luo
Department of Robotic Minimally Invasive Surgery Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People’s Hospital, Chengdu, China
6 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1692792
A diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT
Background: Prostate cancer is one of the most common malignant tumors of the male genitourinary system. The impaired activity of natural killer (NK) cells observed in prostate cancer may contribute to immune evasion. This study aimed to develop robust NK cell-related diagnostic signatures. Methods: Based on NK related genes identified by scRNA-seq analysis, weighted gene co-expression network analysis, least absolute shrinkage and selection operator regression analysis, and machine learning algorithms were used to develop a novel diagnostic model. The expression of diagnostic genes was validated using tumor and adjacent normal tissues collected from prostate cancer patients. The biological functions of KIT as an NK cell related gene were further evaluated in prostate cancer cells. Results: A nine-gene NK cell-related diagnostic signature was developed, including HSPD1 , HSPE1 , CLU , KIT , LAPTM4A , SLC18A2 , TUBA4A , VWA5A , and ZFP36L1 . These genes were validated in independent datasets and showed strong predictive ability for prostate cancer diagnosis (AUC >0.8). Based on the expression profiles of these genes, nine compounds were identified that may influence drug sensitivity in prostate cancer. Furthermore, the expressions of CLU , TUBA4A , and KIT were successfully validated in collected prostate cancer tissue samples. Functional experiments demonstrated that KIT overexpression enhanced the cytotoxicity of NK-92 cells against prostate cancer PC-3 cells, inhibited cancer cell viability, cell migration and invasion, and increased the secretion of cytokines such as IFN-γ, Gzms-A, Gzms-B, and Perforin, as well as the degranulation marker CD107a. Conclusion: This study provides a new understanding of NK cell related gene signatures in prostate cancer diagnosis and highlights KIT as a promising candidate for future therapeutic investigation. Further research is needed to explore the mechanisms underlying the expression of these genes and their roles in the tumor microenvironment.
- 3 June 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1692792
Open AccessA diagnostic signature derived from NK cell related genes in prostate cancer: insights from integrated scRNA-seq and bulk RNA-seq analyses with functional validation of KIT
Background: Prostate cancer is one of the most common malignant tumors of the male genitourinary system. The impaired activity of natural killer (NK) cells observed in prostate cancer may contribute to immune evasion. This study aimed to develop robust NK cell-related diagnostic signatures. Methods: Based on NK related genes identified by scRNA-seq analysis, weighted gene co-expression network analysis, least absolute shrinkage and selection operator regression analysis, and machine learning algorithms were used to develop a novel diagnostic model. The expression of diagnostic genes was validated using tumor and adjacent normal tissues collected from prostate cancer patients. The biological functions of KIT as an NK cell related gene were further evaluated in prostate cancer cells. Results: A nine-gene NK cell-related diagnostic signature was developed, including HSPD1 , HSPE1 , CLU , KIT , LAPTM4A , SLC18A2 , TUBA4A , VWA5A , and ZFP36L1 . These genes were validated in independent datasets and showed strong predictive ability for prostate cancer diagnosis (AUC >0.8). Based on the expression profiles of these genes, nine compounds were identified that may influence drug sensitivity in prostate cancer. Furthermore, the expressions of CLU , TUBA4A , and KIT were successfully validated in collected prostate cancer tissue samples. Functional experiments demonstrated that KIT overexpression enhanced the cytotoxicity of NK-92 cells against prostate cancer PC-3 cells, inhibited cancer cell viability, cell migration and invasion, and increased the secretion of cytokines such as IFN-γ, Gzms-A, Gzms-B, and Perforin, as well as the degranulation marker CD107a. Conclusion: This study provides a new understanding of NK cell related gene signatures in prostate cancer diagnosis and highlights KIT as a promising candidate for future therapeutic investigation. Further research is needed to explore the mechanisms underlying the expression of these genes and their roles in the tumor microenvironment.
- Open Access
- 11 November 2024
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 18 (1) , 1
Correction: Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
- 11 November 2024
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 18 (1) , 1
Open AccessCorrection: Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
- Open Access
- 5 July 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (11) , 4934-4935
A case report of primary mesenchymal sarcoma of the prostate and the thoughts on its treatment
- 5 July 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (11) , 4934-4935
Open AccessA case report of primary mesenchymal sarcoma of the prostate and the thoughts on its treatment
- Open Access
- 27 March 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (8) , 3087-3088
Crossed fused renal ectopia with hydronephrosis: A case report
- 27 March 2023
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (8) , 3087-3088
Open AccessCrossed fused renal ectopia with hydronephrosis: A case report
- 22 March 2023
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (4) , 1659-1667
Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
To summarize surgical experiences with a new modified technique involving extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy based on Da Vinci SI system by reviewing case data, including follow ups, and to evaluate the safety and clinical efficacy of the surgical procedure. The case data from December 2020 to September 2022 of 321 patients undergoing modified single incision (without dedicated PORT) robotic-assisted laparoscopic radical prostatectomy via an extraperitoneal approach were reviewed. All procedures were performed by the same surgeon at our center. Perioperative data and postoperative urinary control, tumor control, and erectile function recovery were assessed. The immediate, 3-months, 6-months, 12-months, 18-months and 24-months complete urinary control rates were 34.3%, 56.6%, 79.7%, 85.7%, 89.6% and 90.7%, respectively; the 3-months, 6-months, 12-months, 18-months and 24-months biochemical recurrence rates were 3.4%, 5.2%, 9.1%, 21.7% and 30.2%, respectively; and for those with normal preoperative erectile function, the 3-months, 6-months, 12-months, 18-months and 24-months postoperative erectile function recovery rates were 52.2%, 60.0%, 70.7%, 72.2% and 73.9%, respectively. The new modified technique involving extraperitoneal single-incision robotic-assisted laparoscopic radical prostatectomy is safe and feasible. This technique has satisfactory surgical results, and this new method results in satisfactory urinary control, tumor control and recovery of erectile function. In addition, this new method is not limited to specific dedicated access devices, which facilitates its application.
- 22 March 2023
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (4) , 1659-1667
Experience with an innovative surgical approach: 321 cases modified extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy without dedicated PORT based on Da Vinci SI system
To summarize surgical experiences with a new modified technique involving extraperitoneal single-incision robot-assisted laparoscopic radical prostatectomy based on Da Vinci SI system by reviewing case data, including follow ups, and to evaluate the safety and clinical efficacy of the surgical procedure. The case data from December 2020 to September 2022 of 321 patients undergoing modified single incision (without dedicated PORT) robotic-assisted laparoscopic radical prostatectomy via an extraperitoneal approach were reviewed. All procedures were performed by the same surgeon at our center. Perioperative data and postoperative urinary control, tumor control, and erectile function recovery were assessed. The immediate, 3-months, 6-months, 12-months, 18-months and 24-months complete urinary control rates were 34.3%, 56.6%, 79.7%, 85.7%, 89.6% and 90.7%, respectively; the 3-months, 6-months, 12-months, 18-months and 24-months biochemical recurrence rates were 3.4%, 5.2%, 9.1%, 21.7% and 30.2%, respectively; and for those with normal preoperative erectile function, the 3-months, 6-months, 12-months, 18-months and 24-months postoperative erectile function recovery rates were 52.2%, 60.0%, 70.7%, 72.2% and 73.9%, respectively. The new modified technique involving extraperitoneal single-incision robotic-assisted laparoscopic radical prostatectomy is safe and feasible. This technique has satisfactory surgical results, and this new method results in satisfactory urinary control, tumor control and recovery of erectile function. In addition, this new method is not limited to specific dedicated access devices, which facilitates its application.
- Open Access
- 25 January 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Preliminary comparison of the modified extraperitoneal free-PORT single incision technique and transabdominal multi-incision robot-assisted laparoscopic radical prostatectomy
To compare the clinical efficacy of an innovative modified single-incision technique without special extraperitoneal PORT with that of transperitoneal multi-incision robot-assisted laparoscopic radical prostatectomy and to explore the feasibility and safety of the former. A retrospective analysis was performed on 259 patients who received robot-assisted laparoscopic radical prostatectomy in the Robot Minimally Invasive Center of Sichuan Provincial People's Hospital between September 2018 and August 2021. Among them were 147 cases involving extraperitoneal single incision with no special PORT (Group A) and 112 cases involving multiple incisions by the transperitoneal method (Group B). Differences in age, PSA level, Gleason score, prostate volume, body mass index, clinical stage, lower abdominal operation history, and lymph node dissection ratio between the two groups were not statistically significant (P > 0.05). All operations were performed by the same operator. In this study, all 259 operations were completed successfully, and there was no conversion. There was no significant difference in transperitoneal blood loss, postoperative hospital stay, positive rate of incision margin, indwelling time of urinary catheter, satisfaction rate of immediate urine control, satisfaction rate of urine control 3 months after operation, positive rate of postoperative lymph node pathology or postoperative pathological stage between the two groups (P > 0.05). There were significant differences in operation time, postoperative exhaust time and incision length (P < 0.05). The modified extraperitoneal nonspecial PORT single-incision technique is safe and feasible for robot-assisted laparoscopic radical prostatectomy, and its curative effect is similar to that of transperitoneal multi-incision RARP. It has the advantages of a short operation time, less impact on the gastrointestinal tract and a more beautiful incision. The long-term effect of treatment needs to be further confirmed by prospective studies.
- 25 January 2023
- Published by Springer Nature in Scientific Reports
- Vol. 13 (1) , 1-8
Open AccessPreliminary comparison of the modified extraperitoneal free-PORT single incision technique and transabdominal multi-incision robot-assisted laparoscopic radical prostatectomy
To compare the clinical efficacy of an innovative modified single-incision technique without special extraperitoneal PORT with that of transperitoneal multi-incision robot-assisted laparoscopic radical prostatectomy and to explore the feasibility and safety of the former. A retrospective analysis was performed on 259 patients who received robot-assisted laparoscopic radical prostatectomy in the Robot Minimally Invasive Center of Sichuan Provincial People's Hospital between September 2018 and August 2021. Among them were 147 cases involving extraperitoneal single incision with no special PORT (Group A) and 112 cases involving multiple incisions by the transperitoneal method (Group B). Differences in age, PSA level, Gleason score, prostate volume, body mass index, clinical stage, lower abdominal operation history, and lymph node dissection ratio between the two groups were not statistically significant (P > 0.05). All operations were performed by the same operator. In this study, all 259 operations were completed successfully, and there was no conversion. There was no significant difference in transperitoneal blood loss, postoperative hospital stay, positive rate of incision margin, indwelling time of urinary catheter, satisfaction rate of immediate urine control, satisfaction rate of urine control 3 months after operation, positive rate of postoperative lymph node pathology or postoperative pathological stage between the two groups (P > 0.05). There were significant differences in operation time, postoperative exhaust time and incision length (P < 0.05). The modified extraperitoneal nonspecial PORT single-incision technique is safe and feasible for robot-assisted laparoscopic radical prostatectomy, and its curative effect is similar to that of transperitoneal multi-incision RARP. It has the advantages of a short operation time, less impact on the gastrointestinal tract and a more beautiful incision. The long-term effect of treatment needs to be further confirmed by prospective studies.
- Open Access
- 26 August 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (2) , 1149-1150
Treatment of the recurrence after radical resection of clear cell renal cell carcinoma
- 26 August 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 46 (2) , 1149-1150
Open AccessTreatment of the recurrence after radical resection of clear cell renal cell carcinoma
- Open Access
- 6 May 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 45 (10) , 2076-2078
A rare postoperative complication of intestinal perforation in retroperitoneal aggressive fibromatosis
- 6 May 2022
- Published by Elsevier in Asian Journal of Surgery
- Vol. 45 (10) , 2076-2078
Open AccessA rare postoperative complication of intestinal perforation in retroperitoneal aggressive fibromatosis